tirzepatide perscription Mounjaro (tirzepatide): Uses, Side Effects,

The results of this study were an important step forward in diabetes care and sparked interest in using peptides that target both GIP and GLP-1

Aroda VR, Bauer R, Hertz CL, Montanya E, Srrig R, Warren ML, et al

Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability

Problem is, I love the tracks in their wrongly tuned pitch